KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.00

Personalized biomarker-based treatment strategy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the biomarker-driven cohorts of the EORTC-HNCG-1559 trial (UPSTREAM).

Rachel Galot, Christophe Le Tourneau, Lisa Licitra, Joël Guigay, Anthony Kong, Ingeborg Tinhofer, Caroline Even, Amaury Daste, Esma Saada-Bouzid, Frédéric Rolland, Stéphanie Henry, Sylvie Rottey, Emmanuel Seront, Annemie Rutten, Athénais van der Elst, Konstantina Tsechilidou, Lieve Dirix, Catherine Fortpied, Ana Joaquim, Anne-Sophie Govaerts, Jean-Pascal Machiels

Eur J Cancer 249 117791

PMID42976409
PMCID-
DOI10.1016/j.ejca.2026.117791
发表日期2026-11-03
入排依据:未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
摘要

摘要

BACKGROUND: Patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have poor prognosis and limited treatment options. Given the molecular heterogeneity of SCCHN, the biomarker-driven UPSTREAM umbrella trial evaluated personalized targeted therapies based on tumor molecular profiling. METHODS: UPSTREAM enrolled patients with post-platinum R/M SCCHN. Fresh tumor biopsies underwent molecular profiling to assign patients to five biomarker-defined cohorts. Cohorts B1-B4 included p16-negative disease: B1 evaluated afatinib in tumors with EGFR and/or HER2 amplification/mutation or high PTEN expression; B2 evaluated afatinib in cetuximab-naïve patients; B3 evaluated palbociclib in CCND1-amplified tumors; and B4 evaluated niraparib in platinum-sensitive disease. B5 evaluated niraparib in p16-positive oropharyngeal carcinoma. B1-B3 were randomized against physician's choice, with 16-week progression-free survival rate (PFSR16W) as the primary endpoint; B4-B5 were single-arm studies with 16-week objective response rate (ORR) as the primary endpoint. RESULTS: Among 250 patients enrolled across five European countries, 152 were assigned to a biomarker-driven cohort. Only B1 met its primary endpoint. In B1, 38 patients received afatinib, with a PFSR16W of 34.2%. Slow recruitment limited B2 to eight patients, with a PFSR16W of 12.5%. In B3, PFSR16W was 16.7% (n = 12). ORRs with niraparib were 3.6% (1/28) in B4 and 6.1% (2/33) in B5. CONCLUSION: UPSTREAM demonstrated the feasibility of a biomarker-driven umbrella trial in R/M SCCHN, but clinical activity of the evaluated targeted therapies was modest. Findings likely reflect the absence of robust oncogenic drivers, limited biomarker validation, and restricted efficacy of single-agent targeted therapy. Improved biomarker selection, next-generation targeted treatments, and rational combinations are needed to advance precision medicine in R/M SCCHN.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。